|
||
Analgesin Dosage |
||
Usual Adult Dose for Ankylosing Spondylitis:
Initial: 250 mg to 500 mg (Analgesin) or 275 mg to 550 mg (Analgesin sodium) orally twice a day. The initial dose for Analgesin sodium controlled-release is two 375 mg tablets (750 mg) orally once a day, one 750 mg tablet orally once a day, or two 500 mg tablets (1000 mg) orally once a day.
Maintenance: May be increased to a daily maximum of 1500 mg (Analgesin) or 1650 mg (Analgesin sodium) in 2 divided doses, for limited periods up to 6 months. In patients who tolerate lower doses well, the dose of Analgesin sodium controlled-release may be increased to two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) orally once a day for limited periods.
Usual Adult Dose for Osteoarthritis:
Initial: 250 mg to 500 mg (Analgesin) or 275 mg to 550 mg (Analgesin sodium) orally twice a day. The initial dose for Analgesin sodium controlled-release is two 375 mg tablets (750 mg) orally once a day, one 750 mg tablet orally once a day, or two 500 mg tablets (1000 mg) orally once a day.
Maintenance: May be increased to a daily maximum of 1500 mg (Analgesin) or 1650 mg (Analgesin sodium) in 2 divided doses, for limited periods up to 6 months. In patients who tolerate lower doses well, the dose of Analgesin sodium controlled-release may be increased to two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) orally once a day for limited periods.
Usual Adult Dose for Rheumatoid Arthritis:
Initial: 250 mg to 500 mg (Analgesin) or 275 mg to 550 mg (Analgesin sodium) orally twice a day. The initial dose for Analgesin sodium controlled-release is two 375 mg tablets (750 mg) orally once a day, one 750 mg tablet orally once a day, or two 500 mg tablets (1000 mg) orally once a day.
Maintenance: May be increased to a daily maximum of 1500 mg (Analgesin) or 1650 mg (Analgesin sodium) in 2 divided doses, for limited periods up to 6 months. In patients who tolerate lower doses well, the dose of Analgesin sodium controlled-release may be increased to two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) orally once a day for limited periods.
Usual Adult Dose for Acute Gout:
750 mg (Analgesin) or 825 mg (Analgesin sodium) orally one time, followed by 250 mg (Analgesin) or 275 mg (Analgesin sodium) every 8 hours until the gouty attack has resolved, usually 2 to 3 days. The recommended dose of Analgesin sodium controlled-release is two to three 500 mg tablets (1000 to 1500 mg) orally on the first day, followed by two 500 mg tablets (1000 mg) orally daily until the attack has subsided.
Usual Adult Dose for Bursitis:
550 mg Analgesin sodium orally once, followed by 550 mg Analgesin sodium every 12 hours, or 275 mg (Analgesin sodium)/250 mg (Analgesin) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg Analgesin sodium or 1000 mg Analgesin. The recommended initial dose of Analgesin sodium controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Adult Dose for Tendonitis:
550 mg Analgesin sodium orally once, followed by 550 mg Analgesin sodium every 12 hours, or 275 mg (Analgesin sodium)/250 mg (Analgesin) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg Analgesin sodium or 1000 mg Analgesin. The recommended initial dose of Analgesin sodium controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Adult Dose for Dysmenorrhea:
550 mg Analgesin sodium orally once, followed by 550 mg Analgesin sodium every 12 hours, or 275 mg (Analgesin sodium)/250 mg (Analgesin) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg Analgesin sodium or 1000 mg Analgesin.
Over-the-counter preparation: Analgesin sodium 220 mg orally every 8 hours as needed. Do not exceed 2 caplets in any 8- to 12-hour period.
The recommended initial dose of Analgesin sodium controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Adult Dose for Pain:
550 mg Analgesin sodium orally once, followed by 550 mg Analgesin sodium every 12 hours, or 275 mg (Analgesin sodium)/250 mg (Analgesin) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg Analgesin sodium or 1000 mg Analgesin.
Over-the-counter preparation: Analgesin sodium 220 mg orally every 8 hours as needed. Do not exceed 2 caplets in any 8- to 12-hour period.
The recommended initial dose of Analgesin sodium controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Geriatric Dose for Pain:
Over-the-counter preparation - 220 mg (Analgesin sodium) orally every 12 hours or 250 mg (Analgesin) orally every 8 hours as needed.
Usual Pediatric Dose for Fever:
Dosage guidelines are based on Analgesin:
Greater than 2 years: 2.5 to 10 mg/kg/dose. Maximum daily dose is 10 mg/kg, given every 8 to 12 hours.
Usual Pediatric Dose for Pain:
Dosage guidelines are based on Analgesin:
Greater than 2 years: 2.5 to 10 mg/kg/dose. Maximum daily dose is 10 mg/kg, given every 8 to 12 hours.
Usual Pediatric Dose for Juvenile Rheumatoid Arthritis:
Dosage guidelines are based on Analgesin:
Greater than or equal to 2 years: 5 mg/kg orally twice a day. Maximum dose: 1000 mg/day.
Ask your doctor before using an antidepressant such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Rapiflux, Sarafem, Selfemra, Symbyax), fluvoxamine (Luvox), paroxetine (Paxil, Pexeva), sertraline (Zoloft), trazodone (Desyrel, Oleptro), or vilazodone (Viibryd). Taking any of these medicines with an NSAID may cause you to bruise or bleed easily.
Ask a doctor or pharmacist if it is safe for you to use Analgesin if you are also using any of the following drugs:
This list is not complete and other drugs may interact with Analgesin. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Table 1: Clinically Significant Drug Interactions with Analgesin
Drugs That Interfere with Hemostasis | |
Clinical Impact: |
|
Intervention: | Monitor patients with concomitant use of Analgesin with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., Analgesin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding. |
Analgesin | |
Clinical Impact: | Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of Analgesin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and Analgesin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone. |
Intervention: | Concomitant use of Analgesin and analgesic doses of Analgesin is not generally recommended because of the increased risk of bleeding. Analgesin is not a substitute for low dose Analgesin for cardiovascular protection. |
ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers | |
Clinical Impact: |
|
Intervention: |
|
Diuretics | |
Clinical Impact: | Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis. |
Intervention: | During concomitant use of Analgesin with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects. |
Digoxin | |
Clinical Impact: | The concomitant use of Analgesin with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. |
Intervention: | During concomitant use of Analgesin and digoxin, monitor serum digoxin levels. |
Lithium | |
Clinical Impact: | NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis. |
Intervention: | During concomitant use of Analgesin and lithium, monitor patients for signs of lithium toxicity. |
Methotrexate | |
Clinical Impact: | Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction). |
Intervention: | During concomitant use of Analgesin and methotrexate, monitor patients for methotrexate toxicity. |
Cyclosporine | |
Clinical Impact: | Concomitant use of Analgesin and cyclosporine may increase cyclosporine’s nephrotoxicity. |
Intervention: | During concomitant use of Analgesin and cyclosporine, monitor patients for signs of worsening renal function. |
NSAIDs and Salicylates | |
Clinical Impact: | Concomitant use of Analgesin with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy. |
Intervention: | The concomitant use of Analgesin with other NSAIDs or salicylates is not recommended. |
Pemetrexed | |
Clinical Impact: | Concomitant use of Analgesin and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity. |
Intervention: | During concomitant use of Analgesin and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration. |
Antacids and Sucralfate | |
Clinical Impact: | Concomitant administration of some antacids (magnesium oxide or aluminum hydroxide) and sucralfate can delay the absorption of Analgesin. |
Intervention: | Concomitant administration of antacids such as magnesium oxide or aluminum hydroxid, and sucralfate with Analgesin is not recommended. |
Cholestyramine | |
Clinical Impact: | Concomitant administration of cholestyramine can delay the absorption of Analgesin. |
Intervention: | Concomitant administration of cholestyramine with Analgesin is not recommended. |
Probenecid | |
Clinical Impact: | Probenecid given concurrently increases Analgesin anion plasma levels and extends its plasma half-life significantly. |
Intervention: | Patients simultaneously receiving Analgesin and probenecid should be observed for adjustment of dose if required. |
Other albumin-bound drugs | |
Clinical Impact: | Analgesin is highly bound to plasma albumin; it thus has a theoretical potential for interaction with other albumin-bound drugs such as coumarin-type anticoagulants, sulphonylureas, hydantoins, other NSAIDs, and Analgesin. |
Intervention: | Patients simultaneously receiving Analgesin and a hydantoin, sulphonamide or sulphonylurea should be observed for adjustment of dose if required. |
Drug/Laboratory Test Interactions | |
Bleeding times | |
Clinical Impact: | Analgesin may decrease platelet aggregation and prolong bleeding time. |
Intervention: | This effect should be kept in mind when bleeding times are determined. |
Porter-Silber test | |
Clinical Impact: | The administration of Analgesin may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-di-nitrobenzene used in this assay. |
Intervention: | Although 17-hydroxy-corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with Analgesin be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used. |
Urinary assays of 5-hydroxy indoleacetic acid (5HIAA) | |
Clinical Impact: | Analgesin may interfere with some urinary assays of 5-hydroxy indoleacetic acid (5HIAA). |
Intervention: | This effect should be kept in mind when urinary 5-hydroxy indoleacetic acid are determined. |
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|